Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 19/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 18/20 | 0.47 |
| ▸ | NQO2 | P16083 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3574624 | 1.00 | MTNR1A (0.58) | MTNR1AMTNR1BNQO2GPR119HTR2C | |
| SCHEMBL11985443 | 1.00 | MTNR1A (0.58) | MTNR1AMTNR1BNQO2GPR119HTR2C | |
| SCHEMBL3579345 | 0.90 | MTNR1A (0.60) | MTNR1AMTNR1BNQO2HTR2C | |
| SCHEMBL3574065 | 0.90 | MTNR1A (0.60) | MTNR1AMTNR1BNQO2HTR2C | |
| SCHEMBL3574771 | 0.88 | MTNR1A (0.74) | MTNR1AMTNR1BNQO2HTR2C | |
| SCHEMBL3580128 | 0.82 | MTNR1A (0.53) | MTNR1AMTNR1BGPR119 | |
| SCHEMBL3574107 | 0.78 | MTNR1A (0.48) | MTNR1AMTNR1BGPR119 | |
| SCHEMBL13705665 | 0.77 | MTNR1A (0.79) | MTNR1AMTNR1BNQO2HTR2C | |
| SCHEMBL3581903 | 0.73 | MTNR1A (0.47) | MTNR1AMTNR1B | |
| SCHEMBL24033681 | 0.72 | PDE4D (0.40) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247429-B2 | Tricyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-8247429-B2 | Tricyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-20100010038-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 00 | 2010-01-14 | — | — | US | disclosed |
| US-20100010038-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 00 | 2010-01-14 | — | — | US | disclosed |
| EP-2098513-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010038-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | MTNR1A, MTNR1B, XDH | MTNR1A 1/4885MTNR1B 2/4885NQO2 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.